WILMINGTON, N.C. & BEND, Ore., Oct 26, 2010 (BUSINESS WIRE) -- PPD, Inc. and Bend Research, Inc. today announced they have entered into a collaboration in the areas of formulation development, ...
DELRAY BEACH, Fla., April 13, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of ...
Major CRO PPD and U.K.-based drug development company Quotient have signed up to a new partnership aimed at shortening timelines, reducing costs and cutting down on paperwork when it comes to making ...
The partnership leverages PPD’s pediatric clinical trial experience, regulatory knowledge, and site and pediatric patient networks, and Quotient’s expertise in pediatric formulation development, drug ...
Sage’s proprietary intravenous (IV) formulation of brexanolone is being developed for the treatment of postpartum depression (PPD) and has been granted Breakthrough Therapy Designation by the FDA and ...
PPD bounced back from a profit slump in the second quarter of 2010 to report operating income up by 10.1% to US$56.8 million for the third quarter ended 30 September. PPD bounced back from a profit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback